News
4d
Medical Device Network on MSNFDA approves Edwards’ TAVR system for asymptomatic aortic stenosis patientsEdwards’ SAPIEN 3 platform becomes the first TAVR system approved by the FDA for asymptomatic severe aortic stenosis patients ...
1mon
GlobalData on MSNMedtronic announces two-year trial outcomes of Evolut TAVRIn the international, multi-centre trial, the Evolut TAVR demonstrated “continued superior” valve performance, according to ...
Data shows, versus surgery, the Evolut™ transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years ...
Edwards Lifesciences’ TAVR platform is the first to be approved in this population. Edwards Lifesciences announced the FDA approved its transcatheter aortic valve replacement platform for ...
Dr. George and the Columbia Valve team discussed new technology from the two largest structural heart companies, the Edwards SAPIEN X4 and the Medtronic Evolut FX. Receive the the latest news, ...
(RTTNews) - Edwards Lifesciences Corp. (EW) Thursday said that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 ...
holding more than 60% of the US TAVR market. But change may be afoot. Medtronic recently released two-year results from a clinical trial comparing its Evolut system to Edwards’ SAPIEN ...
Data shows, versus surgery, the Evolut transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve ...
Data shows, versus surgery, the Evolut transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results